Case Registration in Cell Therapy
Sponsored by Novartis Pharmaceuticals Corporation
Organized by the ISCT Asia Regional Executive Committee
Monday, August 20, 2018 (PDT/CDT) / Tuesday, August 21, 2018 (JST)
19:00 PDT, 22:00 EDT, 11:00 JST (next day)
- Satoshi Takahashi, MD, PhD, Regional Vice-President, ISCT Asia Regional Executive Committee, Associate Professor, Institute of Medical Science University of Tokyo, Japan
Current Status and Future Perspectives of Cellular Therapy Registry in Japan
- Yoshiko Atsuta, MD, PhD, Scientific Director, Japanese Data Center for Hematopoietic Cell Transplantation, Japan
Long Term Follow Up of Recipients of Genetic Modified Cellular Therapies
- Marcelo C. Pasquini, MD, MS, Associate Professor of Medicine, Division of Hematology and Oncology and Senior Scientific Director for Clinical Trials, Center for International Blood and Marrow Transplant Research (CIBMTR®), Department of Medicine, Medical College of Wisconsin, United States
About the Webinar:
The case registration system can contribute to gaining precise activity information. In the hematopoietic stem cell transplantation (HSCT) field, there are at least 3 major systems internationally; CIBMTR (North America), EBMT (Europe) and JDCHCT (Japan) and each registry continues to be a critically valuable resource for understanding and advancing stem cell transplantation and cellular therapy research. Those databases enable users to perform high quality registry studies or support clinical trials, which leads to improvement and better outcome of HSCT and cellular therapy.
Registration for this Webinar has been sponsored by Novartis Pharmaceuticals Corporation.